# Westfield Capital Management

> Westfield Capital Management is a VC fund backing Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 7
- Last investment: Sep 2015
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/53665
- Website: http://www.westfieldcapital.com

Westfield Capital Management is an SEC-registered investment advisor dedicated to providing quality investment management services to institutions and wealthy individuals. Westfield supervises domestic growth equities, with products focusing on each segment of the capitalization spectrum. Our team of 13 investment professionals employs anin-depth, fundamental research process to uncover growth opportunities not yet fully appreciated by the market.Westfield is a client-centric organization. We strive to understand our clients' investment objectives, respect the needs of each individual client entity and offer direct access to our portfolio management team.

## Contacts

5 contacts available for Westfield Capital Management. Shizune tracks 1 team members at Westfield Capital Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/westfield-capital-management?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Health Care | 3 | 43% |
| Medical | 2 | 29% |
| Therapeutics | 2 | 29% |
| Computer | 1 | 14% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 4 | 57% |
| Series D | 1 | 14% |
| Funding Round | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| WILLIAM A. MUGGIA | President, CEO and Chief Investment Officer | 0 | https://shizune.co/investors/profile/william-a-muggia |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SevOne | SevOne provides the only digital infrastructure performance monitoring solution engineered for Speed at Scale for the world’s most demanding service-delivery environments. The patented SevOne ClusterTM architecture leverages distributed computing to monitor any device in the service-delivery path, integrating performance metrics, flows, and logs atscale, while providing answers in seconds to prevent performance-impacting outages. SevOne’s global customer base includes 5 of the 7 top global investment services companies, enterprises, CSPs, MSPs and MSOs. SevOne serves organizations that are looking to complex, dynamic next-generation infrastructure such as software=defined networks, orchestrated containers, and cloud technologies to support their business goals. The company is backed by Bain Capital Ventures and was named a Visionary in Gartner’s 2015 Magic Quadrant for Network Performance Monitoring and Diagnostics. | $47.1M | Series C | Sep 23, 2015 |  |
| Proteolix | Onyx Pharmaceuticals (NASDAQ: ONXX) is a biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases. | $79M | Series C | Sep 08, 2008 |  |
| Collegium Pharmaceutical | Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focusedon building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform. | $20M | Series D | Jul 15, 2008 |  |
| Concert Pharmaceuticals | Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline ofnew chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense. | $37M | Series C | Apr 30, 2008 |  |
| Tepha | Tepha is a medical device firm pursuing the development and commercialization of innovative products based on the company's proprietary biomaterial technology. The technology provides a new class of absorbable biomaterials, known as polyhydroxyalkanoates , which may be tailored to meet unmet needs for medical devices in multiple fields.Tepha's novel, biosynthetically produced materials offer superior performance in flexibility, elasticity, and biocompatibility; and, for its fiber-based products, excellent tensile strength and strength retention. | $10.7M | Series B | Jun 06, 2007 |  |
| BioSET | BioSurface Engineering Technologies, Inc., also known as BioSET, engages in developing proprietary therapeutic peptides as medical devices to improve bone and soft tissue repair. The company focuses on developing devices for orthobiologics applications. Its products include AMPLEX, an implantable combination device of the B2A peptide and asynthetic ceramic scaffold for use as a surgical bone graft implant for lumbar degenerative disc disease, as well as for use in spine, cervical spine, and foot and ankle fusion surgeries. The company also develops products for sports medicine applications based on its F2A peptide; and peptide signaling molecules and various scaffold biomaterials for use in musculoskeletal applications, including trauma, fracture repair, and other soft tissue treatments. BioSurface Engineering Technologies, Inc. was founded in 2001 and is based in Rockville, Maryland. | $11M |  | Jun 05, 2007 |  |
| Collegium Pharmaceutical | Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focusedon building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform. | $5.5M | Series C | Nov 03, 2006 |  |

7 of 7 investments shown.

## Co-investors
- [The Vertical Group](https://shizune.co/investors/profile/the-vertical-group) — VC Fund, 3 deals together
- [Boston Millennia Partners](https://shizune.co/investors/profile/boston-millennia-partners) — VC Fund, 2 deals together
- [Brookside Capital](https://shizune.co/investors/profile/brookside-capital) — VC Fund, 2 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together
- [Advanced Technology Ventures](https://shizune.co/investors/profile/advanced-technology-ventures) — VC Fund, 1 deal together
- [Bain Capital Ventures](https://shizune.co/investors/profile/bain-capital-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Westfield Capital Management invest in?

Westfield Capital Management invests primarily in Biotechnology, Health Care and Medical startups, most often at Series C and Series D stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Westfield Capital Management?

Public channels for Westfield Capital Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Westfield Capital Management?

The team at Westfield Capital Management includes WILLIAM A. MUGGIA (President, CEO and Chief Investment Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co